LABORATORY NEWS
-
QIAGEN Receives FDA Clearance For QIAstat-Dx Mini Panel To Improve Precision In Outpatient Respiratory Treatment
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024.
- GeneCentric Therapeutics Launches EXpressCT Liquid Biopsy Platform
- Hardy Diagnostics Announces Exclusive Partnership For The US And Canada With Gradientech For The Commercialization Of The Quickmic® System
- Space-Based 3D Cell Culture Research Paves The Way For New Cancer Therapies
- Inaugural Global Symposium On Interventional Radiation Protection To Focus On Keeping Lab-Based Clinicians Safe
ARCHIVED NEWSLETTER
- 10.22.24 -- Sterility Assurance: The Fundamentals
- 10.08.24 -- How CSL Behring Worked With EMA/FDA To Develop Hemgenix Potency Assays
- 09.24.24 -- 2024 Emerging Trends In Cleanroom Technologies
- 09.10.24 -- Bacterial Endotoxin Testing, Part 4: Key Tests For Endotoxin Detection
- 08.27.24 -- Is Your Lab Ready For A LIMS Implementation?
This website uses cookies to ensure you get the best experience on our website. Learn more